Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574401 | 0.78 | ERN1 (0.53) | ERN1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL15260648 | 0.76 | CYP19A1 (0.49) | CYP19A1CA1CA2CA9CKS1B | |
| SCHEMBL29177680 | 0.75 | CYP19A1 (0.48) | CYP19A1CA1CA2CA9CKS1B | |
| SCHEMBL29986368 | 0.75 | CYP19A1 (0.48) | CYP19A1CKS1BSKP2APP | |
| SCHEMBL28401036 | 0.75 | CYP19A1 (0.48) | CYP19A1CA1CA2CA9APP | |
| SCHEMBL6512953 | 0.75 | PDE10A (0.60) | PDE10AALDH1A1MAPTL3MBTL1HSP90AA1 | |
| SCHEMBL29940575 | 0.75 | PDE10A (0.60) | PDE10AALDH1A1MAPTL3MBTL1HSP90AA1 | |
| SCHEMBL3048215 | 0.74 | CYP19A1 (0.48) | ERN1CYP19A1CA1CA2CA9 | |
| SCHEMBL2880254 | 0.74 | IKBKB (0.42) | CYP19A1CA1CA2CA9KDM4E | |
| SCHEMBL5670993 | 0.74 | CYP19A1 (0.47) | CYP19A1CA1CA2CA9CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1899299-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002635-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY11, P2RY1, P2RY13 | ERN1 1750/4885PDE10A 338/4885CYP19A1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.